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Summary
Objectives: The objective of this study was to describe the pattern and trends of antibiotic
resistance of Pseudomonas aeruginosa over a six-year period in a Saudi Arabian hospital.
Methods: This was a retrospective study of the antibiotic resistance of outpatient and inpatient
isolates of P. aeruginosa. Only one isolate per patient per year was included in the study.
Results: During the study period a total of 2679 isolates of P. aeruginosa were available for
analysis. Outpatient isolates constituted 48% of the total number, and of these 23.4% were
obtained from wound cultures. For the inpatient isolates, 33.6% and 30% were obtained from the
respiratory tract and wounds, respectively. There was no significant increase in the resistance
rates of outpatient isolates to the tested antibiotics over time. On the other hand, inpatient
isolates showed a statistically significant increase in resistance rates to piperacillin, ceftazidime,
imipenem, and ciprofloxacin (p < 0.001). Over the study period, the resistance rates of out-
patient and inpatient isolates to piperacillin, ceftazidime, imipenem, and ciprofloxacin were
4.6% and 11.5%, 2.4% and 10%, 2.6% and 5.8%, and 3% and 6%, respectively. Gentamicin
demonstrated the highest resistance among all tested aminoglycosides for outpatient isolates
(6%) and inpatient isolates (6.7%). Resistance to more than two classes of antibiotics was present
in 1—2% of inpatient isolates and in 0% of outpatient isolates.
Conclusion: Antibiotic resistance continues to be a problem especially in inpatient isolates and is
likely to be related to increased antibiotic use. Thus, continued monitoring of antibiotic
resistance is of great importance to ensure the proper use of antibiotics and to detect any
increasing trends in resistance.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Tel.: +966 3 877 3524; fax: +966 3 877 3790.
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Bacterial resistance to commonly prescribed antibiotics is
associated with increased morbidity, mortality, and health-
care costs.1,2 The rate of antibiotic resistance to Pseudomo-
nas aeruginosa is increasing in many parts of the world, in
particular the rates of resistance to b-lactams, aminoglyco-
sides, and fluoroquinolones.3 Regional variations in antibiotic
resistance exist for different organisms, including P. aerugi-
nosa, and this may be related to the difference in antibiotic
prescribing habits.4
Local and regional surveillance of antibiotic resistance
provides better understanding of the global trends in anti-
biotic resistance.5 Periodic testing and analysis of antibiotic
resistance would enable physicians to detect trends in the
resistance pattern to commonly prescribed antibiotics in a
given organism.6 There are few data available in Saudi Arabia
on the resistance of P. aeruginosa isolates.7 Moreover, there is
only one study addressing the pattern of antibiotic resistance
of P. aeruginosa in Saudi Arabia over an extended period of
time.7 Thus, in this study we evaluated the trends of the
susceptibility pattern of inpatient and outpatient isolates of
P. aeruginosa in Saudi Aramco Medical Services Organization
(SAMSO) in Dhahran, Saudi Arabia over a six-year period
(1998—2003). SAMSO, which has five intensive care units,
provides medical care to Saudi Aramco employees and their
dependents, with >1 000 000 outpatient visits and >24 000
admissions annually.
Methods
We analyzed, retrospectively, the in vitro antibiotic suscept-
ibility of P. aeruginosa from 1998 to 2003. Only one isolate per
patient per year was included in the analysis. There were no
large intra-hospital P. aeruginosa outbreaks during the study
period. Gram-negative bacilli were identified to the species
level and antibiotic susceptibility testing was done by an
automated system (Vitek Biomerieux, France). Results of the
antibiotic susceptibility testing were interpreted according
to guidelines of the National Committee for Clinical Labora-
tory Standards (NCCLS).8 P. aeruginosa American Type Cul-
ture Collection (ATCC) 27853 was used as a quality control
strain. For the purpose of this study, percentage of resistance
was calculated as the percent of intermediately susceptible
and resistant organisms in relation to the total tested iso-
lates. Multidrug resistance of P. aeruginosa was defined as
resistance of isolates to three or more classes of antibiotics
(imipenem, ceftazidime, ciprofloxacin, piperacillin, or anTable 1 Resistance pattern of inpatient isolates by site
Blood Respiratory
Piperacillin 10.1% (69) 16.7% (258)
Ceftazidime 9.7% (93) 13.4% (379)
Imipenem 4.4% (91) 8.3% (359)
Amikacin 0.0% (93) 2.7% (378)
Gentamicin 5.2% (97) 8.2% (390)
Tobramycin 1.1% (88) 3.4% (355)
Ciprofloxacin 2.2% (92) 7.7% (387)
The values in parentheses indicate the total tested isolates.aminoglycoside). The bacterial isolates were considered as
inpatient isolates if they were cultured more than 48 hours
after admission or within 30 days of hospital discharge.
Otherwise, the isolates were considered as coming from
outpatients.
Statistical analyses
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS version 10.0). The
difference in resistance rates between inpatient and out-
patient isolates was assessed by two sample proportion tests.
The annual percentage of resistance of P. aeruginosa was
calculated and analyzed for an increase or decrease in the
trends over the study period using linear trend analysis. If the
p value of the Chi-square test for association was significant
(<0.05) then a trend existed. Furthermore, the Chi-square
test for trends had to be significant, regardless of whether
there was a departure from a linear trend. Whenever there
was a significant trend in the resistance, the p value was
given. The regression coefficient indicating a change in the y-
axis (percentage of resistance), divided by the change in the
x-axis (years) was calculated.9,10 A negative slope () indi-
cated a decrease in resistance, whereas a positive slope (+)
confirmed an increase of resistance over time.
Results
A total of 3918 isolates of P. aeruginosa were identified in
the study period. After excluding duplicate isolates, the
remaining 2679 isolates constituted the sample of analysis
in this study. Outpatient isolates constituted 48% of the
total with the remaining isolates from inpatient cases. Of
the outpatient isolates, 23.4% were obtained from wound
cultures, 17.5% from urine, and 9.5% from respiratory
cultures. Of the inpatient isolates, 33.6%, 30%, and
18.5% were obtained from respiratory, wound, and urine
cultures, respectively. The resistance pattern of P. aerugi-
nosa per site of isolation is shown in Table 1 (outpatients)
and in Table 2 (inpatients). For the inpatient cases, isolates
of P. aeruginosa from a respiratory source showed higher
rates of resistance to piperacillin ( p = 0.01), ceftazidime
( p < 0.001), and imipenem ( p = 0.03) compared to other
isolates (Table 1), whereas outpatient urinary isolates
showed higher rates of resistance to ciprofloxacin
( p < 0.01) and amikacin ( p = 0.01) when compared to iso-
lates from other sources (Table 2).Urine Wound Other
10.9% (138) 8.5% (234) 2.2% (46)
9.7% (174) 0.8% (377) 4.5% (66)
6.5% (170) 3.9% (331) 0.0% (57)
1.2% (173) 2.6% (351) 0.0% (62)
4.8% (248) 7.3% (400) 4.3% (69)
1.8% (223) 2.6% (347) 0.0% (62)
6.5% (184) 5.8% (398) 1.5% (68)
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Table 2 Resistance pattern of outpatient isolates by site
Blood Respiratory Urine Wound Other
Piperacillin 0.0% (57) 3.8% (342) 6.2% (125) 5.3% (169) 7.0% (86)
Ceftazidime 1.2% (84) 2.2% (494) 3.0% (165) 2.9% (276) 2.3% (132)
Imipenem 3.9% (76) 1.7% (462) 3.3% (152) 3.6% (250) 2.5% (119)
Amikacin 1.3% (79) 3.8% (506) 1.2% (165) 0.7% (270) 0.0% (133)
Gentamicin 3.4% (88) 7.3% (522) 7.1% (225) 4.3% (300) 4.2% (146)
Tobramycin 1.2% (81) 1.7% (463) 3.4% (204) 1.5% (262) 0.0% (121)
Ciprofloxacin 1.2% (86) 2.7% (519) 6.3% (175) 0.03% (296) 2.1% (146)
The values in parentheses indicate the total tested isolates.
Table 3 Trends in antibiotic resistance rates (%) of outpatient isolates of P. aeruginosa (1998—2003)
1998 1999 2000 2001 2002 2003 p Value CRa
Piperacillin 1% (97) 3.2% (62) 6.7% (30) 7.7% (130) 4.5% (332) 4.6% (128) 0.304 0.509
Ceftazidime 0.8% (124) 0% (119) 3% (167) 3.8% (287) 2.4% (328) 2.4% (126) 0.203 0.606
Imipenem 2% (96) 2% (90) 4% (148) 2.3% (264) 2.4% (335) 3.2% (126) 0.474 0.37
Amikacin 1% (99) 0% (90) 3% (194) 3% (307) 1.5% (335) 2.3% (128) 0.32 0.493
Gentamicin 4.5% (156) 4% (146) 7% (202) 7% (311) 5.6% (338) 6% (128) 0.284 0.526
Tobramycin 0.6% (155) 0.8% (132) 4.4% (137) 1.6% (258) 1.2% (325) 3.2% (124) 0.427 0.404
Ciprofloxacin 4% (125) 2.3% (194) 2.6% (194) 1.6% (309) 4.2% (337) 4.7% (127) 0.49 0.355
The values in parentheses indicate the total tested isolates.
a CR denotes regression coefficient.Annual trends in antimicrobial resistance of
outpatient and inpatient isolates (1998—2003)
The trends in resistance rates of outpatient isolates of P.
aeruginosa are shown in Table 3. The overall resistance
rates to the tested antibiotics showed no significant sta-
tistical increase over the study period. The resistance rate
to ciprofloxacin ranged from 1.6% in 2001 and 4% in 1998
and 4.7% in 2003 ( p = 0.49) and ceftazidime resistance
increased from 0.8% in 1998 to 2.4% in 2003 ( p = 0.203).
Imipenem resistance remained relatively low over the
study period and ranged from 2% in 1998 to 3.2% in 2003
( p = 0.47).
Table 4 shows the rates of antibiotic resistance of inpa-
tient isolates to P. aeruginosa. Inpatient isolates showed
increasing annual resistance rates to all tested antibiotics.
In particular, the resistance rates to ciprofloxacin increased
from 2.3% in 1998 to 10.7% in 2003 ( p = 0.026) and ceftazi-Table 4 Trends in antibiotic resistance rates (%) of inpatient iso
1998 1999 2000 2001
Piperacillin 3.5% (144) 4.8% (104) 7.4% (27) 8.7
Ceftazidime 6% (170) 9% (178) 10.4% (163) 11.5
Imipenem 1.4% (143) 5.6% (143) 1.3% (153) 7.7
Amikacin 2% (144) 2% (144) 0% (172) 1%
Gentamicin 4% (213) 7.6% (211) 2% (177) 7.6
Tobramycin 1.4% (212) 1.5% (194) 0.8% (131) 2%
Ciprofloxacin 2.3% (172) 6.4% (188) 4.7% (171) 5.2
The values in parentheses indicate the total tested isolates.
a CR denotes regression coefficient.dime resistance increased from 6% in 1998 to 12.3% in 2003
( p = 0.01). Imipenem resistance increased from 1.4% in 1998
to 11% in 2003 ( p = 0.042).
Comparison of resistance rates between
outpatient and inpatient isolates
The resistance rates of inpatient isolates of P. aeruginosa
were almost twice the rates of resistance of outpatient
isolates to piperacillin, ceftazidime, imipenem, and cipro-
floxacin ( p < 0.001) (Figure 1). There was, however, no
significant statistical difference in resistance rates to ami-
kacin, tobramycin, and gentamicin between outpatient and
inpatient isolates ( p > 0.05). Piperacillin was the least effec-
tive antibiotic followed by ceftazidime in the inpatient iso-
lates. Ceftazidime resistance, a predictive of derepression of
the chromosomal AmpC b-lactamase gene or efflux pumps,
was detected in 2.4% and 10% of outpatient and inpatientlates of P. aeruginosa (1998—2003)
2002 2003 p Value CRa
% (112) 14% (239) 16% (119) 0.001 0.979
% (225) 11.2% (239) 12.3% (114) 0.01 0.917
% (207) 7% (243) 11% (119) 0.042 0.828
(235) 3.3% (243) 4.2% (119) 0.9 0.561
% (236) 9% (246) 11.6% (121) 0.7 0.738
(195) 2.6% (232) 8% (111) 0.65 0.754
% (230) 7.7% (247) 10.7% (121) 0.026 0.866
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Figure 1 Comparison of the resistance rates of outpatient and
inpatient isolates of P. aeruginosa. The clustered column graph
shows the percentage of resistance of outpatient isolates (solid
column) and inpatient isolates (dotted column). The numbers
above each bar represent the total number of tested isolates.isolates, respectively. Ciprofloxacin resistance remained
relatively low at 3% for outpatient isolates and 6% for inpa-
tient isolates.
Multidrug-resistant P. aeruginosa
Multidrug-resistant (MDR) P. aeruginosa was rare among clin-
ical isolates, ranging between 1% for ciprofloxacin, gentami-
cin, and ceftazidime, and 2% for piperacillin, gentamicin, and
ceftazidime for inpatient isolates. However, there were no
isolates with resistance to all classes of antibiotics. No MDR
isolates were obtained from outpatient strains.
Discussion
Monitoring antibiotic resistance of bacterial agents and eval-
uating resistance rates for inpatient and outpatient bacterial
isolates may assist in the appropriate selection of empiric
antibiotic treatment in the proper setting. The few available
studies on the resistance of P. aeruginosa in Saudi Arabia are
limited to a small number of bacterial isolates.7 Moreover,
these studies do not address the issue of annual trends in
resistance to different antimicrobial agents. In this study, we
analyzed the annual trends in antibiotic resistance of P.
aeruginosa in SAMSO over a six-year period.
In this study, the resistance rate of P. aeruginosa to piper-
acillin was relatively low (4—11%). In a previous study from
Saudi Arabia, the resistance rate to piperacillin/tazobactam
was 18.2%.7 However, the study included only 704 isolates. In
the Meropenem Yearly Susceptibility Test Information Collec-
tion (MYSTIC) program study (1999—2002) in the USA, the rate
of resistance to piperacillin/tazobactam was 8.4—13.7% in
1999—200111 and 9.7% in 2003.12 A higher rate of resistance
of P. aeruginosa to piperacillin was reported from Jamaica and
had reached 25%.13 Similarly, 32% of P. aeruginosa in patients
with cystic fibrosis in the UK were resistant to piperacillin.14In this study, we demonstrated that the annual resistance
rates of piperacillin had increased from 1 to 4.6% in the
outpatient isolates and from 3.5 to 16% in the inpatient
isolates in 1998 and 2003, respectively. Similarly, in a study
from San Francisco the annual piperacillin resistance rates
increased from 10% in 1996 to 30% in 1999.15 Thus, the
resistance rate to piperacillin in the current study is similar
or close to those reported from other parts of Saudi Arabia
and those from the USA. However, the resistance rate was at
least two-fold less than the reported rates from Jamaica and
the UK.131,4 The differences in the resistance rates are
probably related to differences in antibiotic use especially
in selected groups of the population like cystic fibrosis
patients in the UK study.14
Ceftazidime resistance in this study was 2.4% and 10% for
outpatient and inpatient isolates, respectively. Similar to the
resistance rates of the outpatient isolates in our study, the
resistance rate to ceftazidime was 2.5% in a study from Trini-
dad16andtheresistancerateof inpatient isolateswassimilarto
that reported from France (8.5%).17 However, the resistance
rate was much less than that reported from Turkey where it
reached36%.18 Inanother study fromSaudiArabia,ceftazidime
resistance was detected in 18.2% of clinical isolates.7 Ceftazi-
dime resistance is usually due to selection of P. aeruginosa
strains with derepression of the chromosomal AmpC b-lacta-
mase gene or efflux pumps. Increased prevalence of ceftazi-
dime-resistant P. aeruginosa is related to increased use of b-
lactam antibiotics such as amoxicillin and ceftazidime. Thus,
the differences in the resistance rates usually correlate with
the prescribing habits of each hospital and the selective pres-
sure of certain antibiotics. Unfortunately, figures on the
amount of ceftazidime used in our hospital were not available
for correlation with the resistance pattern.
Resistance of P. aeruginosa to ciprofloxacin is a major
problem in many parts of the world. In our study, the resis-
tance rate of inpatient isolates to ciprofloxacin increased
from 2.6% in 1998 to 10.7% in 2003. A much higher rate of
increase in the resistance of ciprofloxacin has been observed
in intensive care unit (ICU) isolates in Denver, USA.19 In that
study, ciprofloxacin resistance increased from 22% in 1998 to
54% in 2002.19 The difference in the rate of resistance
between these studies is probably related to selective pres-
sure of fluoroquinolones especially in a high-risk population in
the ICU. The cumulative resistance rate of inpatient isolates
of P. aeruginosa in our study was 6% and is similar to the rates
reported from one study in Saudi Arabia.7 However, resis-
tance rates of P. aeruginosa to ciprofloxacin are much higher
in other parts of the world compared to those in our study.
Ciprofloxacin resistance exceeds 50% in Italy20 and 30% in
patients with cystic fibrosis in the UK.14 In a study of surgical
site infections in the USA, the resistance rate of P. aeruginosa
to ciprofloxacin was 16%.21 However, a lower rate of resis-
tance was reported from Trinidad (2.6%).16 The difference in
the rate of ciprofloxacin resistance is usually related to the
intensity of the use of fluoroquinolones.
In our study, the resistance rate to imipenem was rela-
tively low and accounted for 2.6% and 5.8% of outpatient and
inpatient isolates, respectively. In a previous report from
Saudi Arabia, the prevalence of imipenem resistance was
9.2%.7 This rate was comparable to the rate in the recent
MYSTIC study (9.5%).12 A similar rate of resistance was
obtained from blood isolates in France (6.4%).17 A much
P. aeruginosa resistance in a Saudi Arabian hospital 113higher rate of imipenem resistance was reported from Croa-
tia where resistance ranged from 10.2% to 31.6%.22 Geogra-
phical variation in the resistance rates of P. aeruginosa may
be related to the antibiotic prescribing habits in different
parts of the world.
The rate of MDR-P. aeruginosa is increasing inmany parts of
the world and poses a serious therapeutic dilemma. In some
institutes, the treatment of MDR-P. aeruginosa is being limited
to polymyxin B.23 In this study, the rate of MDR-P. aeruginosa
from inpatient isolates was low (1—2%) compared to other
studies from Saudi Arabia and the USA. In a study of resistance
rates ofP. aeruginosa in intensive care unit patients in theUSA,
the rate of MDR ranged between 4% in 1993 and 14% in 2002.19
In a study from Riyadh, Saudi Arabia, MDR-P. aeruginosa was
detected in 6.4% of P. aeruginosa.7 However, in that particular
study MDR was defined as resistance to 2 classes of anti-
biotics. Thedifference in the resistance rates between the two
studies from Saudi Arabia may have been related to the
difference in the definitions used (>2 classes vs. 2 classes).
Thus, on-going surveillance of the rate of increase in antibiotic
resistance and the presence of MDR at each institute is critical
for the selection of appropriate antimicrobial therapy.
In this study, inpatient isolates were more resistant to
ceftazidime, piperacillin, imipenem, and ciprofloxacin com-
pared to outpatient isolates. Moreover, inpatient isolates of P.
aeruginosa showed an increased rate of resistance to piper-
acillin, ceftazidime, and ciprofloxacin, whereas outpatient
isolates showed no statistically significant increase in the
resistance rate to the tested antibiotics over the study period.
The differential increase in the rate of resistance between
inpatient and outpatient isolates is interesting. This observa-
tion is probably related to the high exposure of inpatient
isolates to more and broader spectrum antibiotics than out-
patient isolates.24 A similar observation of a high rate of
increase in the resistance of P. aeruginosa has been observed
in ICU isolates in the USA.19 A pattern of significant stepwise
increase in the frequency of antimicrobial resistance has also
been observed in a study from Italy.24 The highest resistance
rates occurred among isolates from ICU patients followed by
isolates from non-ICU inpatients, and the least resistance was
observed in outpatient isolates.24 However, we found no
increase in the antibiotic resistance of outpatient isolates of
P. aeruginosa over the study period. Other investigators have
reported an increase in the resistance rate of outpatient
urinary P. aeruginosa to some but not all antibiotics.25 How-
ever, that study did not address the trend in a statistical way.25
In conclusion, the finding in this study of the low resis-
tance of outpatient isolates to P. aeruginosa is encouraging.
The increase in resistance rates of inpatient isolates to some
antibiotics such as ceftazidime, ciprofloxacin, and imipenem
calls for judicious use of antibiotics to limit further increase
in resistance rates. Antibiotic resistance is usually related to
the amount of antibiotics being used in humans and non-
humans. However, one limitation of this study is that we had
no available data on antibiotic consumption for correlation
with the resistance rates.
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